Inhibikase Therapeutics Inc. (IKT) at a glance

Inhibikase Therapeutics Inc. (IKT) is a micro-cap Healthcare company. It trades at $2.41, with a P/E of 3.6 and a 0% profit margin. It does not pay a dividend. Vestovix scores it 66/100 overall. Its strongest dimension is Value (95/100) and its weakest is Income (40/100). Its volatility is roughly in line with the market.

Price

$2.41

Market cap

$220.5M

P/E ratio

3.6

Dividend yield

None

Beta

0.97

52-week range

$1.33 to $2.54